A unique Novo Nordisk legal challenge to the Medicare drug pricing program could have big implications for the pharma ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

When should six drugs count as one? That question is at the heart of an unusual challenge that the pharma company Novo Nordisk is pursuing against the federal government. And the answer could have ...

The FDA had rejected the companies’ initial application in 2023, requesting additional data after the pharma firms reported ...

Eli Lilly gains ground with Orforglipron’s success, showing growth potential and risks from momentum and tariffs. Read why ...

Seeking Alpha analyst Stephen Ayers shares his views on which weight-loss drug stock looks most attractive for investors ...

President Donald Trump has ordered the Department of Health and Human Services to standardize Medicare payments in an effort ...

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

Eli Lilly plans to manufacture its new weight-loss pill in the US for patients around the world as Trump presses companies to ...

Health-care companies slid after signs of stress in UnitedHealth Group's business. The largest U.S. insurer by enrollees cut its growth projections, citing hitches with its key Medicare business.

A surprise executive order could delay drug price cuts and supercharge profits for the industry's biggest players ...

The wide-ranging executive order signed by Trump aims to reduce healthcare costs. It comes one day after the Trump ...